

ASX Release

Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement preclinical data suggests safe administration with and, importantly, enhancement of effect of a commonly used class of disease-modifying prescription medications

Highlights

- Potential adjuvant effect in reducing inflammation with the co-administration of GaRP with disease-modifying medications
- Potential to reduce the dose of disease-modifying medications known to have devastating side-effects
- GaRP does not affect the uptake or potential activity of probiotics
- Anatara on track to an anticipated partnering deal milestone by 2H 2020

BRISBANE & MELBOURNE, 19th December 2019: Anatara Lifesciences (ASX:ANR) is pleased to provide an update on its GaRP dietary supplement preclinical milestones, which is being developed to specifically target two human gastrointestinal disorders, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Anatara's GaRP dietary supplement has the potential to be used in a wide range of chronic gastrointestinal (GI) indications. As such, it was important that the Anatara team establish that the product would not interfere with the effectiveness of commonly used prescription medications indicated for GI disorders, as well as other commonly used complementary and alternative medicines, such as probiotics.

Significantly, preclinical data suggests the co-administration of GaRP with a commonly used disease-modifying medication (these medications are the backbone of current inflammatory bowel disease treatment regimens) demonstrated a significant increase in the reduction in inflammation. This is an exciting observation of an adjuvant effect and suggests the potential to significantly reduce the dose of relevant prescription medications. If this clinically-relevant finding translates into humans, patients will have the advantage of being able to reduce their dose of disease-modifying medications which are renowned for their devastating side-effects, such as sepsis. These findings are currently being confirmed in animal models of IBD.

Anatara has also demonstrated, using *in-vitro* gut models, that its GaRP dietary supplement did not affect the uptake or potential activity of probiotics.

Anatara's CEO, Mr Steven Lydeamore said, "This data adds to the strong scientific proof that our GaRP dietary supplement has the potential to be game changing. The activity of the product is due to its unique formulation and has the added advantage of being able to be fast-tracked to consumers, as the traditional, formal drug pathway for approval is not required."

"Our proprietary product has demonstrated that it not only has the potential to manage the devastating symptoms experienced by IBD and IBS patients, but may also address the underlying causes of these chronic bowel conditions. Meeting this milestone keeps Anatara on track to an anticipated partnering deal by 2H 2020."



IBS is the most common GI condition affecting approximately 11% of the global population¹, while IBD affects an estimated five million people globally²

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS³ and IBD⁴ patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients perceive the risk-benefit of CAMs to be favourable, patients are willing to spend significant amounts of money on CAMs. In 2018, expenditure on gastrointestinal supplements and over-the-counter (OTC) digestive remedies in the US alone was US\$8 billion^{5,6}.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Sue MacLeman Chair, Anataro Lifesciences Ltd +61 (0) 437 211 200 smacleman@anataro.com

¹ Clinical Gastroenterology and Hepatology 2012; 10, 712-721.

² Crohn's and Colitis Australia.

³ Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.

⁴ Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712.

⁵ Mintel's 2018 Digestive Health U.S., July 2019.

⁶ 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.